Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects

Tumor-infiltrating lymphocyte (TIL) therapy has evolved from a pioneering experimental approach to a clinically validated treatment strategy, underscored by the recent approval of lifileucel (Amtagvi) by the Food and Drug Administration (FDA) for advanced melanoma refractory to existing therapies. I...

Full description

Saved in:
Bibliographic Details
Main Authors: Sarker Drishty Badhon, Gonzalez Marian M., Martinez Sophia, Sang Qing-Xiang Amy
Format: Article
Language:English
Published: EDP Sciences 2025-01-01
Series:Visualized Cancer Medicine
Subjects:
Online Access:https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20250003/vcm20250003.html
Tags: Add Tag
No Tags, Be the first to tag this record!